Engineered immune cells take on tough leukemia
NCT ID NCT03620058
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new approach for adults with acute lymphoblastic leukemia that has not responded to chemotherapy. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack cancer cells with CD22 and CD19 proteins, and infuse them back. The goal is to see if this treatment is safe and can shrink or eliminate the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modified immune cells (CAR T-cells) targeting CD22 and CD19 proteins
What this could lead to
If successful, this could provide a new treatment option for adults with hard-to-treat acute lymphoblastic leukemia that has not responded to chemotherapy.
What could go wrong
This is an early phase 1 trial with only 23 participants, so results may not apply to everyone. Side effects like cytokine release syndrome are possible, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States